JP2003523325A5 - - Google Patents

Download PDF

Info

Publication number
JP2003523325A5
JP2003523325A5 JP2001548102A JP2001548102A JP2003523325A5 JP 2003523325 A5 JP2003523325 A5 JP 2003523325A5 JP 2001548102 A JP2001548102 A JP 2001548102A JP 2001548102 A JP2001548102 A JP 2001548102A JP 2003523325 A5 JP2003523325 A5 JP 2003523325A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
abl
pdgf
acceptable salt
tyrosine kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2001548102A
Other languages
English (en)
Japanese (ja)
Other versions
JP2003523325A (ja
Filing date
Publication date
Priority claimed from IT1999MI002711A external-priority patent/ITMI992711A1/it
Application filed filed Critical
Publication of JP2003523325A publication Critical patent/JP2003523325A/ja
Publication of JP2003523325A5 publication Critical patent/JP2003523325A5/ja
Pending legal-status Critical Current

Links

JP2001548102A 1999-12-27 2000-12-22 受容体チロシンキナーゼ阻害剤とα１−酸性糖タンパク質結合性有機化合物との組合せ Pending JP2003523325A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IT1999MI002711A ITMI992711A1 (it) 1999-12-27 1999-12-27 Composti organici
IT99A002711 1999-12-27
PCT/EP2000/013161 WO2001047507A2 (en) 1999-12-27 2000-12-22 Combinations of receptor tyrosine kinase inhibitor with an a1-acidic glycoprotein binding compound

Publications (2)

Publication Number Publication Date
JP2003523325A JP2003523325A (ja) 2003-08-05
JP2003523325A5 true JP2003523325A5 (https=) 2008-02-14

Family

ID=11384195

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2001548102A Pending JP2003523325A (ja) 1999-12-27 2000-12-22 受容体チロシンキナーゼ阻害剤とα１−酸性糖タンパク質結合性有機化合物との組合せ

Country Status (18)

Country Link
US (2) US20030125343A1 (https=)
EP (1) EP1250140B1 (https=)
JP (1) JP2003523325A (https=)
CN (1) CN1304005C (https=)
AR (1) AR030179A1 (https=)
AT (1) ATE432069T1 (https=)
AU (1) AU2171901A (https=)
BR (1) BR0016817A (https=)
CA (1) CA2394944A1 (https=)
CO (1) CO5271710A1 (https=)
DE (1) DE60042283D1 (https=)
ES (1) ES2326307T3 (https=)
HK (1) HK1050993A1 (https=)
IT (1) ITMI992711A1 (https=)
PE (1) PE20010991A1 (https=)
PT (1) PT1250140E (https=)
TW (1) TWI246917B (https=)
WO (1) WO2001047507A2 (https=)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE369894T1 (de) * 2000-11-22 2007-09-15 Novartis Pharma Gmbh Kombination enthaltend ein mittel zur verminderung von vegf-aktivität und ein mittel zur verminderung von egf-aktivität
AU2002315388A1 (en) 2001-06-21 2003-01-08 Ariad Pharmaceuticals, Inc. Novel phenylamino-pyrimidines and uses thereof
US7323469B2 (en) 2001-08-07 2008-01-29 Novartis Ag 7H-pyrrolo[2,3-d]pyrimidine derivatives
GB0119249D0 (en) 2001-08-07 2001-10-03 Novartis Ag Organic compounds
DE10141650C1 (de) 2001-08-24 2002-11-28 Lohmann Therapie Syst Lts Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen
US20050043409A1 (en) * 2001-10-25 2005-02-24 Chen Ying-Nan Pan Combinations comprising a selective cyclooxygenase-2 inhibitor
GB0201508D0 (en) 2002-01-23 2002-03-13 Novartis Ag Organic compounds
CA2479257A1 (en) * 2002-03-21 2003-10-02 Dana-Farber Cancer Institute, Inc. Inhibition of cell death responses induced by oxidative stress
AU2007201830C1 (en) * 2002-04-23 2017-09-07 Novartis Pharma Ag High drug load tablet
GB0209265D0 (en) 2002-04-23 2002-06-05 Novartis Ag Organic compounds
WO2004026930A2 (en) * 2002-06-26 2004-04-01 The Ohio State University Research Foundation The method for reducing inflammation using sti-571 or its salt
JP2005533838A (ja) * 2002-07-24 2005-11-10 ノバルティス　アクチエンゲゼルシャフト 未分化甲状腺癌を処置するための４−（４−メチルピペラジン−１−イルメチル）−ｎ−［４−メチル−３−（４−ピリジン−３−イル）ピリミジン−２−イルアミノ］フェニル］−ベンズアミド
DE60313339T2 (de) * 2002-07-31 2008-01-03 Critical Outcome Technologies, Inc. Protein tyrosin kinase inhibitoren
GB0222514D0 (en) 2002-09-27 2002-11-06 Novartis Ag Organic compounds
US7629347B2 (en) * 2002-10-09 2009-12-08 Critical Outcome Technologies, Inc. Protein tyrosine kinase inhibitors
AU2003268185A1 (en) * 2003-08-25 2005-04-11 Dana-Farber Cancer Institute Inc. Method of treating mixed lineage leukemia gene-rearranged acute lymphoblastic leukemias
CA2538523A1 (en) * 2003-09-19 2005-03-31 Novartis Ag Treatment of gastrointestinal stromal tumors with imatinib and midostaurin
TW200517114A (en) * 2003-10-15 2005-06-01 Combinatorx Inc Methods and reagents for the treatment of immunoinflammatory disorders
DK1720853T3 (en) † 2004-02-11 2016-03-29 Natco Pharma Ltd HIS UNKNOWN POLYMORPH FORM OF IMATINIBMYLYLATE AND PROCEDURE FOR PREPARING IT
MXPA06015237A (es) 2004-06-29 2007-12-10 Amgen Inc Pirrolo[2-3-d]pirimidinas que modulan la actividad de ack1 y lck.
JP2008508358A (ja) * 2004-08-02 2008-03-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド アリール−アミノ置換ピロロピリミジンマルチキナーゼ阻害化合物
ATE519759T1 (de) 2004-12-30 2011-08-15 Exelixis Inc Pyrimidinderivate als kinasemodulatoren und anwendungsverfahren
US20070059359A1 (en) * 2005-06-07 2007-03-15 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of non-micronised (4-chlorophenyl)[4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
US20060275365A1 (en) * 2005-06-07 2006-12-07 Thomas Backensfeld Immediate-release and high-drug-load pharmaceutical formulations of micronised (4-chlorophenyl) [4-(4-pyridylmethyl)phthalazin-1-yl] and salts thereof
DE602006015994D1 (de) * 2005-06-23 2010-09-16 Novartis Ag Verfahren zur behandlung von soliden tumoren einschliesslich der verabreichung einer kombination mit imatinib und einem effluxpumpenhemmer
EP1979349B1 (en) * 2005-12-21 2010-07-28 Abbott Laboratories Anti-viral compounds
US7910595B2 (en) * 2005-12-21 2011-03-22 Abbott Laboratories Anti-viral compounds
WO2007081517A2 (en) 2005-12-21 2007-07-19 Abbott Laboratories Anti-viral compounds
CA2649755C (en) * 2006-04-20 2014-12-02 Janssen Pharmaceutica N.V. Method of inhibiting c-kit kinase
EP2043651A2 (en) * 2006-07-05 2009-04-08 Exelixis, Inc. Methods of using igf1r and abl kinase modulators
US8236950B2 (en) 2006-12-20 2012-08-07 Abbott Laboratories Anti-viral compounds
EP2121681B1 (en) 2007-01-11 2015-04-15 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US20080248548A1 (en) * 2007-04-09 2008-10-09 Flynn Daniel L Modulation of protein functionalities
EP2081556A1 (en) * 2007-09-25 2009-07-29 Teva Pharmaceutical Industries Ltd. Stable imatinib compositions
CA2710039C (en) * 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
EP2247596A2 (en) 2008-01-11 2010-11-10 Natco Pharma Limited Novel pyrazolo [3, 4 -d] pyrimidine derivatives as anti -cancer agents
MX353308B (es) 2008-05-21 2018-01-08 Ariad Pharma Inc Derivados fosforosos como inhibidores de cinasa.
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
EP2318406B1 (en) 2008-07-17 2016-01-27 Critical Outcome Technologies, Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2381777A4 (en) 2008-12-12 2012-08-08 Ariad Pharma Inc AZAINDOL DERIVATIVES AS KINASEHEMMER
ITRM20090578A1 (it) * 2009-11-10 2011-05-11 Noi Per Voi Onlus Nuove composizioni per il trattamento di leucemie chemioresistenti e/o di leucemie potenzialmente chemioresistenti.
EP2552915B1 (en) 2010-04-01 2017-07-19 Critical Outcome Technologies Inc. Compounds for the treatment of hiv
US20120115878A1 (en) 2010-11-10 2012-05-10 John Vincent Calienni Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
TR201010618A2 (tr) * 2010-12-20 2012-07-23 Bi̇lgi̇ç Mahmut İmatinib içeren bir oral dozaj formu ve bu oral dozaj formunun üretimi
PL394169A1 (pl) 2011-03-09 2012-09-10 Adamed Spółka Z Ograniczoną Odpowiedzialnością Kompozycja farmaceutyczna metanosulfonianu imatinibu do napełniania jednostkowych postaci dawkowania oraz sposób jej wytwarzania
EP2704572B1 (en) 2011-05-04 2015-12-30 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US20160015708A1 (en) 2012-02-21 2016-01-21 Ranbaxy Laboratories Limited Stable dosage forms of imatinib mesylate
WO2013169401A1 (en) 2012-05-05 2013-11-14 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in egfr-driven cancers
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CN105828822B (zh) 2013-08-14 2019-10-18 诺华股份有限公司 用于治疗癌症的组合疗法
WO2017078647A1 (en) 2015-11-05 2017-05-11 Koçak Farma Ilaç Ve Kimya Sanayi Anonim Şirketi Pharmaceutical compositions of imatinib
EP3257499A1 (en) 2016-06-17 2017-12-20 Vipharm S.A. Process for preparation of imatinib methanesulfonate capsules
US12390468B2 (en) 2019-01-23 2025-08-19 Novartis Ag Crystalline forms of a succinate salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5587459A (en) * 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5750493A (en) * 1995-08-30 1998-05-12 Raymond F. Schinazi Method to improve the biological and antiviral activity of protease inhibitors
US20030069174A1 (en) * 1997-03-10 2003-04-10 Ludwig Pichler Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation
CO4940418A1 (es) * 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
WO2001004125A1 (en) * 1999-07-13 2001-01-18 Kyowa Hakko Kogyo Co., Ltd. Staurosporin derivatives
DE60037345T2 (de) * 1999-12-10 2008-11-13 Pfizer Products Inc., Groton Pyrrolo(2,3-d)pyrimidin-Verbindungen

Similar Documents

Publication Publication Date Title
JP2003523325A5 (https=)
CA2490907A1 (en) Amide derivative
RU2003114752A (ru) Лечение желудочно-кишечных стромальных опухолей
WO2005039485A3 (en) Gsk-3 inhibitors and uses thereof
RU2233273C3 (ru) Ароматические азотсодержащие 6-членные циклические соединения и фармацевтическая композиция
BRPI0114870B8 (pt) uso de 4-(4-metilpiperazin-1-ilmetil)-n-[4-metil-3-(4-piridin-3-il)pirimidin-2-amino)fenil]-benzamida para a fabricação de composições farmacêuticas para tratamento de tumores estromais gastrointestinais
PL392652A1 (pl) Kombinacja zawierająca N-{5-[4-(4-metylo-piperazyno-metylo)-benzoiloamido]-2-metylofenylo}-4-(3-pirydylo)-2-pirymidyno-aminę oraz środek chemoterapeutyczny, jej zastosowanie, kompozycja farmaceutyczna ją zawierająca oraz zestaw zawierający taką kombinację
NO20052927L (no) 2,4,6-trisubstituerte pyrimidiner av fosfotidylinositol (PI) 3-kinaseinhibitorer og deres anvendelse ved behandling av kreft
CA2551529A1 (en) Amide derivative and medicine
EP1521749B8 (en) PHENYL-(4-(3-PHENYL-1H-PYRAZOL-4-YL)-PYRIMIDIN-2-Yl)-AMINE DERIVATIVES
RU93043528A (ru) Моногидрат 5-(2-(4-(1,2-бензотиазол-3-ил)-1-пиперазинил)этил)-6-хлор-1,3-дигидро-2н-индол-2-он хлоргидрата, способ его получения, фармацевтическая композиция, способ лечения
WO2004024078A3 (en) Dihydroxypyridopyrazine-1,6-dione compounds useful as hiv integrase inhibitors
CA2542105A1 (en) Compounds and compositions as protein kinase inhibitors
WO2005039586A1 (en) Use of pyridinyl-pyrimidinylamino-benzamide derivatives for the treatment of amyloid related disorders
US20170143716A1 (en) Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity
RU2008143703A (ru) ПРИМЕНЕНИЕ ИНГИБИТОРОВ c-Src В КОМБИНАЦИИ С ПИРИМИДИЛАМИНОБЕНЗАМИДОМ ДЛЯ ЛЕЧЕНИЯ ЛЕЙКОЗА
CA2439268C (en) Combination comprising a signal transduction inhibitor and an epothilone derivative
AR031679A1 (es) Una composicion farmaceutica
JP2005527523A5 (https=)
MXPA04001364A (es) Uso de bibn4096 en combinacion con otros farmacos anti-migrana para el tratamiento de migrana, composicion y equipo.
HK1047548A1 (zh) 包含有米氮平和哲比隆的治疗抑郁症及其它机能紊乱症的合成药物
CA2473202A1 (en) Pharmaceutical composition for regeneration of cirrhotic liver
JP2002542281A5 (https=)
TNSN06182A1 (en) COMBINATION OF (a) N-{5-[4-(4-METHYL-PYPERAZINO-METHYL)-BENZOYLAMIDO] -2-METHYLPHENYL} -4-(3-PYRIDIL)-2-PYRIMIDINE-AMINE AND (b) AT LEAST ONE HYPUSINATION INHIBITOR AND USE THEREOF
CA2504665A1 (en) Combination of a nitrogen mustard analogue and imatinib for the treatment of chronic lymphocytic leukemia